Orum Therapeutics Appoints Chad May as Chief Scientific Officer
Orum Therapeutics announced the appointment of Chad May, Ph.D., as Chief Scientific Officer to drive innovation in degrader-antibody conjugates (DACs).
Dr. May has over 20 years of experience in oncology and immunology, advancing ADCs, T-cell engagers, and other therapeutics from concept to clinical stages.
Previously, Dr. May was CSO at Serotiny (integrated into Johnson & Johnson), SVP of R&D at Maverick Therapeutics, and held leadership roles at Pfizer and ImClone Systems.
As CSO, he will oversee scientific strategy, discovery, translational research, and preclinical development for Orum's TPD²® pipeline targeting cancer and other diseases.
Orum Therapeutics is pioneering cell-specific targeted protein degraders (TPD²®) with antibody precision for oncology applications.